Neoplasms

Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Neoplasm Metastasis

Thromboembolism

Venous Thromboembolism

Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Fibrinolytic Agents

Anticoagulants

All Drugs and Chemicals

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Heparin

Calcium heparin

Tinzaparin sodium

In this study the investigators will determine the safety and effectiveness of Tinzaparin in preventing blood clots for up to 12 months of treatment.

The purpose of this study is to use long-term administration of a low molecular weight heparin (tinzaparin) for primary treatment and secondary prophylaxis of venous thromboembolism in patients with cancer. We will determine the efficacy (recurrent VTE) and safety (major hemorrhage) of this approach. Secondarily, we will analyze the outcome of patients in terms of survival and response to therapy versus matched controls. We will also determine baseline levels of markers of hemostasis, fibrinolysis, and angiogenesis and will follow changes with treatment as well as correlate levels of these plasma markers with outcomes, including recurrent venous thromboembolism, major hemorrhage,and survival.

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

Celgene Corporation

University of Southern California

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer	NCT00981903	Venous Thromboe... Cancer	Tinzaparin sodi...	18 Years -	University of Southern California
Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer	NCT00981903	Venous Thromboe... Cancer	Tinzaparin sodi...	18 Years -	University of Southern California

Spots Global Cancer Trial Database for vte in cancer patients